Success Metrics

Clinical Success Rate
84.8%

Based on 39 completed trials

Completion Rate
85%(39/46)
Active Trials
5(7%)
Results Posted
26%(10 trials)
Terminated
7(9%)

Phase Distribution

Ph phase_1
6
8%
Ph phase_3
16
21%
Ph early_phase_1
2
3%
Ph phase_2
21
28%
Ph not_applicable
10
13%
Ph phase_4
13
17%

Phase Distribution

8

Early Stage

21

Mid Stage

29

Late Stage

Phase Distribution68 total trials
Early Phase 1First-in-human
2(2.9%)
Phase 1Safety & dosage
6(8.8%)
Phase 2Efficacy & side effects
21(30.9%)
Phase 3Large-scale testing
16(23.5%)
Phase 4Post-market surveillance
13(19.1%)
N/ANon-phased studies
10(14.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.3%

39 of 48 finished

Non-Completion Rate

18.8%

9 ended early

Currently Active

5

trials recruiting

Total Trials

75

all time

Status Distribution
Active(7)
Completed(39)
Terminated(9)
Other(20)

Detailed Status

Completed39
unknown20
Terminated7
Recruiting3
Not yet recruiting2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
75
Active
5
Success Rate
84.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (2.9%)
Phase 16 (8.8%)
Phase 221 (30.9%)
Phase 316 (23.5%)
Phase 413 (19.1%)
N/A10 (14.7%)

Trials by Status

not_yet_recruiting23%
terminated79%
completed3952%
unknown2027%
withdrawn23%
recruiting34%
active_not_recruiting23%

Recent Activity

Clinical Trials (75)

Showing 20 of 75 trialsScroll for more
NCT04294641Phase 2

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Completed
NCT06983756

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

Not Yet Recruiting
NCT05300477Phase 4

Pharmacological Countermeasures for High Altitude

Active Not Recruiting
NCT05931718

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

Recruiting
NCT06590155Early Phase 1

Erythropoietin in HIE Neonate

Not Yet Recruiting
NCT06542393Phase 2

PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)

Recruiting
NCT05395195Phase 3

Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)

Recruiting
NCT05325073Phase 4

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

Active Not Recruiting
NCT06135259Phase 3

Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus

Unknown
NCT06178835Phase 4

EPO for Postop Delirium in Elderly Patients

Completed
NCT03882060Not Applicable

Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients

Unknown
NCT03061565

Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury

Completed
NCT03339596Phase 2

Effects of Erythropoietin for Cognitive Side-effects of ECT

Completed
NCT00003138Phase 3

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Completed
NCT03315897Phase 2

Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders

Completed
NCT05734716Phase 4

Colorado-Oregon Altitude Study

Completed
NCT05704894Phase 3

Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens

Unknown
NCT02811263Phase 3

High-dose Erythropoietin for Asphyxia and Encephalopathy

Completed
NCT03007537Not Applicable

The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury

Terminated
NCT05080049Phase 3

Erythropoietin to Improve Critical Care Patient Outcomes

Unknown

Drug Details

Intervention Type
OTHER
Total Trials
75